Delcath Systems, Inc. (DCTH) is a Healthcare stock trading at $11.71 (as of 2026-06-18), with a market capitalization of $372.14M and a trailing P/E of 1172.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers in the United States and Europe. It develops and provides the HEPZATO kit, a melphalan for injection/hepatic delivery system, and supplies the CHEMOSAT hepatic delivery system device for use with melphalan at medical centers in Europe.